查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1611871

馮維勒布蘭德疾病治療藥物市場：依疾病類型、治療方法、給藥途徑分類 - 全球預測 2025-2030

Von Willebrand Disease Treatment Market by Disease Type (Acquired VWD, Type 1, Type 2), Treatment (Clot-Stabilizing, Desmopressin, Replacement Therapies), Route of Administration - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年血管性血友病治療市值為6.5312億美元，預計2024年將達到7.1876億美元，複合年成長率為11.30%，2030年將達到13821.2億美元，預計將達到1000萬美元。

馮·維勒布蘭德病 (VWD) 治療包括旨在控制以馮·維勒布蘭德因子缺乏或功能障礙為特徵的出血性疾病的治療方法，馮·維勒布蘭德因子對血液凝固很重要。對有效 VWD 治療的需求源於其在減少出血傾向和改善患者生活品質方面的作用。治療方法包括預防性治療和急性出血管理，並用於各種醫療環境，包括醫院、診所和居家醫療。最終用途主要包括醫療保健提供者、患者和致力於客製化治療方法的研究機構。市場開拓洞察表明，成長受到認知和診斷率提高、生物技術進步導致治療方法改進以及政府對制定血友病治療策略的支持的強烈影響。然而，高昂的治療成本和準確診斷工具的複雜性構成了限制市場擴張的挑戰。另一個限制是與某些治療方法相關的潛在副作用，這可能會影響患者的依從性。

主要市場統計
基準年[2023] 6.5312 億美元
預測年份 [2024] 71876萬美元
預測年份 [2030] 1,382.12 百萬美元
複合年成長率（%） 11.30%

個人化醫療和基因療法的開發存在新的商機，提供有針對性的和潛在的治療選擇。先進生技藥品和重組藥物等技術創新提供了一條透過提高治療效果和減少副作用來滿足市場需求的途徑。公司應該投資與在這些創新方面處於領先地位的研究機構進行合作研究。該市場競爭激烈但前景廣闊，主要企業都專注於全面的管道開拓和策略聯盟來擴大市場。為了抓住這些機會，鼓勵公司在其策略中優先考慮研發、監管合規和以患者為中心的方法。儘管監管障礙和市場競爭方面的挑戰仍然存在，但堅持創新和跨部門合作提供了巨大的成長潛力。透過解決這些限制並與技術進步保持一致，公司可以在 VWD 治療領域獲得競爭優勢。

市場動態：針對快速發展的馮維勒布蘭德病藥物市場揭示的關鍵市場洞察

供應和需求的動態交互作用正在改變馮維勒布蘭德病藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 受馮維樂布蘭氏症影響的人數不斷增加
    • 增加患者援助計劃並增加醫療支出
    • 政府努力提高創新治療的有效性和成功率
  • 市場限制因素
    • 與馮維勒布蘭氏症藥物相關的高成本
  • 市場機會
    • 馮維勒布蘭氏症治療產品核可數量增加
    • 持續開發治療馮維樂布蘭氏症的新治療方法和診斷工具
  • 市場挑戰
    • 對血管性血友病治療藥物缺乏認知

波特五力：駕馭馮維樂布蘭氏症藥物市場的策略工具

波特的五力架構是了解馮維勒布蘭德疾病治療藥物市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解血管性血友病藥物市場的外部影響

外部宏觀環境因素在塑造血管性血友病治療藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解血管性血友病治療藥物市場的競爭狀況

對馮維勒布蘭德疾病治療藥物市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣馮維勒布蘭德疾病治療市場供應商的績效評估

FPNV 定位矩陣是評估馮維勒布蘭德疾病治療市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製馮維勒布蘭德疾病治療藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對馮維勒布蘭德疾病治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 馮·維勒布蘭德病患者數量增加
      • 病患援助計劃的增加和醫療成本的上升
      • 政府努力提高創新治療方法的有效性和成功率
    • 抑制因素
      • 與馮維勒布蘭氏症藥物相關的高成本
    • 機會
      • 馮維勒布蘭氏症治療產品核可數量增加
      • 持續開發治療馮維樂布蘭氏症的新治療方法和診斷工具
    • 任務
      • 對血管性血友病治療藥物缺乏認知
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章馮維樂布蘭德疾病治療藥物市場：依疾病類型

  • 獲得性VWD
  • 類型1
  • 2型
  • 類型3

第7章 馮維樂布蘭氏症藥物市場（按治療）

  • 血栓穩定
  • 去氨加壓素
  • 替代療法

第8章馮維勒布蘭德疾病治療藥物市場：依給藥途徑

  • 注射
  • 口服

第9章：美洲血管性血友病藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區血管性血友病藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲馮維勒布蘭德病藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Accredo Health Group, Inc.
  • Affinity Biologicals Incorporated
  • ARUP Laboratories
  • AstraZeneca PLC
  • Baxter Healthcare Corporation
  • Bayer AG
  • Bio Products Laboratory Ltd.
  • Biogen Inc.
  • Bristol Myers Squibb
  • CSL Limited
  • F. Hoffmann-La Roche AG
  • Ferring Pharmaceuticals Inc
  • Genentech Inc.
  • Grifols, SA
  • Laboratory Corporation of America Holdings
  • Novo Nordisk A/S
  • Octapharma AG
  • Pfizer Inc.
  • Sanofi SA
  • Siemens Healthcare GmbH
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
Product Code: MRR-B168537791C5

The Von Willebrand Disease Treatment Market was valued at USD 653.12 million in 2023, expected to reach USD 718.76 million in 2024, and is projected to grow at a CAGR of 11.30%, to USD 1,382.12 million by 2030.

Von Willebrand Disease (VWD) treatment encompasses therapies aimed at managing bleeding disorders characterized by a deficiency or dysfunction of the von Willebrand factor, critical for blood clotting. The necessity for effective VWD treatments stems from their role in reducing bleeding tendencies and improving patients' quality of life. Applications include prophylactic treatments and acute bleeding management, employed in diverse medical settings such as hospitals, clinics, and home care. The end-use scope primarily spans across healthcare providers, patients, and research institutes working on tailored treatment regimens. Market insights reveal that growth is strongly influenced by increasing awareness and diagnosis rates, advancements in biotechnology leading to refined therapies, and governmental support in developing hemophilia care strategies. However, high treatment costs, coupled with the complexity of creating accurate diagnostic tools, are challenges that restrain market expansion. Another limitation is the potential adverse reactions related to certain therapies, impacting patient adherence.

KEY MARKET STATISTICS
Base Year [2023] USD 653.12 million
Estimated Year [2024] USD 718.76 million
Forecast Year [2030] USD 1,382.12 million
CAGR (%) 11.30%

Emerging opportunities lie in the development of personalized medicine and gene therapies, offering targeted and potentially curative options. Technological innovations, such as advanced biologics and recombinant products, present pathways to meet market demands by enhancing treatment efficacy and reducing adverse effects. Companies should invest in collaborations with research institutions to spearhead these innovations. The market's nature is competitive yet promising, with key players focusing on comprehensive pipeline development and strategic partnerships to expand their reach. To capture these opportunities, firms are advised to prioritize R&D, regulatory compliance, and patient-centric approaches in their strategies. While challenges persist in terms of regulatory hurdles and market competition, persevering through innovation and cross-sector collaborations offers substantial growth potential. By addressing these limitations and aligning with technological advancements, businesses can secure a competitive edge in the VWD treatment landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Von Willebrand Disease Treatment Market

The Von Willebrand Disease Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in the number of people suffering from Von Willebrand disease
    • Increase in patient assistance programs and growing healthcare expenditure
    • Government initiatives to increase the efficacy and success rates of innovative treatments
  • Market Restraints
    • High cost associated with Von Willebrand disease treatment
  • Market Opportunities
    • Increasing number of product approvals for Von Willebrand disease treatment
    • Ongoing development of new treatments and diagnostic tools for Von Willebrand disease treatment
  • Market Challenges
    • Lack of awareness related to Von Willebrand disease treatment

Porter's Five Forces: A Strategic Tool for Navigating the Von Willebrand Disease Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Von Willebrand Disease Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Von Willebrand Disease Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Von Willebrand Disease Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Von Willebrand Disease Treatment Market

A detailed market share analysis in the Von Willebrand Disease Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Von Willebrand Disease Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Von Willebrand Disease Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Von Willebrand Disease Treatment Market

A strategic analysis of the Von Willebrand Disease Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Von Willebrand Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include Accredo Health Group, Inc., Affinity Biologicals Incorporated, ARUP Laboratories, AstraZeneca PLC, Baxter Healthcare Corporation, Bayer AG, Bio Products Laboratory Ltd., Biogen Inc., Bristol Myers Squibb, CSL Limited, F. Hoffmann-La Roche AG, Ferring Pharmaceuticals Inc, Genentech Inc., Grifols, S.A., Laboratory Corporation of America Holdings, Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi S.A., Siemens Healthcare GmbH, Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Von Willebrand Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Acquired VWD, Type 1, Type 2, and Type 3.
  • Based on Treatment, market is studied across Clot-Stabilizing, Desmopressin, and Replacement Therapies.
  • Based on Route of Administration, market is studied across Injection and Oral.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in the number of people suffering from Von Willebrand disease
      • 5.1.1.2. Increase in patient assistance programs and growing healthcare expenditure
      • 5.1.1.3. Government initiatives to increase the efficacy and success rates of innovative treatments
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with Von Willebrand disease treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing number of product approvals for Von Willebrand disease treatment
      • 5.1.3.2. Ongoing development of new treatments and diagnostic tools for Von Willebrand disease treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness related to Von Willebrand disease treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Von Willebrand Disease Treatment Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Acquired VWD
  • 6.3. Type 1
  • 6.4. Type 2
  • 6.5. Type 3

7. Von Willebrand Disease Treatment Market, by Treatment

  • 7.1. Introduction
  • 7.2. Clot-Stabilizing
  • 7.3. Desmopressin
  • 7.4. Replacement Therapies

8. Von Willebrand Disease Treatment Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Injection
  • 8.3. Oral

9. Americas Von Willebrand Disease Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Von Willebrand Disease Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Von Willebrand Disease Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Accredo Health Group, Inc.
  • 2. Affinity Biologicals Incorporated
  • 3. ARUP Laboratories
  • 4. AstraZeneca PLC
  • 5. Baxter Healthcare Corporation
  • 6. Bayer AG
  • 7. Bio Products Laboratory Ltd.
  • 8. Biogen Inc.
  • 9. Bristol Myers Squibb
  • 10. CSL Limited
  • 11. F. Hoffmann-La Roche AG
  • 12. Ferring Pharmaceuticals Inc
  • 13. Genentech Inc.
  • 14. Grifols, S.A.
  • 15. Laboratory Corporation of America Holdings
  • 16. Novo Nordisk A/S
  • 17. Octapharma AG
  • 18. Pfizer Inc.
  • 19. Sanofi S.A.
  • 20. Siemens Healthcare GmbH
  • 21. Sun Pharmaceutical Industries Limited
  • 22. Takeda Pharmaceutical Company Limited
  • 23. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. VON WILLEBRAND DISEASE TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. VON WILLEBRAND DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. VON WILLEBRAND DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VON WILLEBRAND DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VON WILLEBRAND DISEASE TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ACQUIRED VWD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 1, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 3, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLOT-STABILIZING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. VON WILLEBRAND DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. VON WILLEBRAND DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023